Amphastar Pharmaceuticals (AMPH) Accumulated Expenses (2016 - 2026)
Amphastar Pharmaceuticals has reported Accumulated Expenses over the past 13 years, most recently at $115.8 million for Q4 2025.
- For Q4 2025, Accumulated Expenses fell 8.52% year-over-year to $115.8 million; the TTM value through Dec 2025 reached $115.8 million, down 8.52%, while the annual FY2025 figure was $115.8 million, 8.52% down from the prior year.
- Accumulated Expenses for Q4 2025 was $115.8 million at Amphastar Pharmaceuticals, down from $150.3 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $198.7 million in Q2 2023 and troughed at $63.7 million in Q4 2022.
- A 5-year average of $102.2 million and a median of $83.7 million in 2021 define the central range for Accumulated Expenses.
- Biggest five-year swings in Accumulated Expenses: surged 198.38% in 2023 and later tumbled 49.96% in 2024.
- Year by year, Accumulated Expenses stood at $67.3 million in 2021, then dropped by 5.33% to $63.7 million in 2022, then increased by 6.57% to $67.9 million in 2023, then surged by 86.29% to $126.5 million in 2024, then decreased by 8.52% to $115.8 million in 2025.
- Business Quant data shows Accumulated Expenses for AMPH at $115.8 million in Q4 2025, $150.3 million in Q3 2025, and $124.7 million in Q2 2025.